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Abstract
Several cell death modes, each with a unique feature and mode of inducing cell 
death have been established. Cell death occurring under physiological conditions 
is primarily caused by apoptosis, which is a non-inflammatory or silent process, 
whereas necroptosis or pyroptosis is triggered by pathogen invasion, which stimu-
lates the immune system and induces inflammation. In physiology, clearing dead 
cells and associated cellular debris is necessary since billions of cells die during 
mammalian embryogenesis and every day in adult organisms. For degradation, 
dead cells produced by apoptosis are quickly engulfed by macrophages. This chapter 
will present a description of the phagocytosis of dead and dying cells, by a process 
known as efferocytosis. Macrophages and, to a lesser degree, other ‘professional’ 
phagocytes (such as monocytes and dendritic cells) and ‘non-professional’ phago-
cytes, such as epithelial cells, conduct efferocytosis. Recent discoveries have shed 
light on this mechanism and how it works to preserve homeostasis of tissue, repair 
of tissue and health of the organism. Caspases are a large family of proteases of 
cysteine acting in cascades. A cascade leading to activation of caspase 3 mediates 
apoptosis and is responsible for killing cells, hiring macrophages, and presenting 
a “eat me” signal(s). If macrophages do not effectively engulf apoptotic cells, they 
undergo secondary necrosis and release intracellular materials that reflect a molecu-
lar pattern associated with injury, which can lead to autoimmune diseases. Here, 
the processes of efferocytosis are illustrated and the pathophysiological effects that 
which occur when this phase is abrogated are highlighted.
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1. Introduction
In multicellular species, cell death and the efficient clearance of dying cells are 
fundamental processes that preserve homeostasis. Cells engage in their demise in 
virtually all physiological and most pathological scenarios through a controlled 
cascade of signaling events (‘regulated’ cell death) [1] Damaged or redundant cells 
die in a regulated manner and are replaced by new cells derived from progenitors of 
stem cells [2]. Cell death is essential for growth; during mammalian embryogenesis 
and development, billions of cells are destroyed in order to form new structures 
and sustain organ function [3, 4]. When addressing pathological events, including 
tissue damage and infections, significant numbers of cells often die. Cell death must 
Regulation and Dysfunction of Apoptosis
2
be carefully controlled; extensive damage caused by heat, mechanical compression 
or osmotic pressure, for example, can cause necrosis of cells, release their intracel-
lular content to the surrounding environment, and contribute to the activation 
of inflammatory immune pathways that can harm healthy cells and tissues sur-
rounding them. In both homeostasis and disease, removal of cellular corpses is 
necessary. The phagocyte engulfment of dead cells, a multistep mechanism known 
as efferocytosis, enables cellular components to be recycled by multicellular organ-
isms. Autoimmune diseases and other diseases may occur when the disposal of cell 
corpses is faulty. While the degradation and recycling of the mass of a cell are typi-
cal features in the clearance of any dead cell, certain cell clearance characteristics 
are specific to a particular mode of cell death. Depending on their mode of death, 
dying cells can expose and secrete signals that attract phagocytes, favor their swal-
lowing, or encourage a return to tissue homeostasis. Via regulation of macrophage 
function following efferocytosis, different forms of cell death may also confer pro-
inflammatory or anti-inflammatory signals. There are several cases in which uncou-
pled phenomena are cell death and corpse disposal, meaning cell death does not 
follow disposal immediately. The shedding of dead intestinal epithelial cells from 
the tip of the villus to the intestinal lumen 5 is one such example. Conversely, cells 
engulf and destroy healthy neighbouring cells in the course of entosis. Although the 
responsible mechanisms are usually different from those for the removal of dead 
cells, [5–11] shared aspects have been identified. Nonetheless, dying cells are easily 
cleared by efferocytosis in the vast majority of cases, and such uncoupled events are 
not further considered herein. Here we summarise our current understanding of 
the mechanisms of efferocytosis and how the physiology of the organism is affected 
by efferocytosis, including inflammation and adaptive immune response results. 
Every day, several hundred billion cells die and are replaced by newly formed cells. 
Senescent neutrophils die and are then phagocytized in the bone marrow, liver, 
and spleen by macrophages [7, 8], while senescent red blood cells are recognized 
and phagocytized by spleen and liver macrophages [7, 8]. In the small intestine, 
senescent enterocytes are shed into the intestinal lumen [11]. Cells infected with 
bacteria or viruses undergo autonomous necrosis of the cells or are destroyed by the 
immune system. Macrophages as a whole do not recognize these cells, and necrotic 
cells release materials that may activate the immune system. Inflammation caused 
by a bacterial or viral infection requires significant white blood cell development, 
and these cells rapidly die when the infection ceases. Additionally, by inhibiting 
the synthesis of purines, DNA, or RNA or by cross-linking or intercalating DNA, 
various anticancer drugs destroy tumour cells.
2. Programmed cell death
Originally, programmed cell death in the sense of insect development was 
described by Lockshin and Williams [2]. Subsequently, Kerr et al. [12] noted two 
morphologically distinct forms of cell death in humans, apoptosis and necrosis, 
through ultrastructural study. The cells swell in necrosis, with the rupture of plasma 
membranes and release of cellular components; the cells shrink with integral yet 
ruffling plasma membranes in apoptosis, and nuclei are condensed and fragmented. 
To avoid the release of intracellular elements, apoptotic cells are rapidly phagocy-
tized by macrophages. This mechanism prevents inflammatory factors from being 
released and is thus called the death of clean cells. “Programmed cell death” and 
“apoptosis” are also used synonymously, because apoptosis occurs in developing 
embryos or in cells that die under physiological conditions. The cell death occur-
ring during inflammation or infection with a necrotic morphology was also found 
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to be programmed or regulated by gene products and was classified as necroptosis 
and pyroptosis [13]. In addition, non-apoptotic cell death was observed during 
the development of Caenorhabditis elegans [14] and Drosophila metamorphosis [15], 
suggesting that cell death can occur through a non-apoptotic mechanism in animal 
development. Programmed cell death should therefore not be used as a synonym for 
apoptosis; it should, as originally described, be reserved for the cell death that takes 
place in animal development [2].
2.1 Apoptosis
In animal growth, apoptosis plays a significant role. For instance, apoptosis 
removes interdigital cells, non-functional nerve cells, and activated lymphocytes. 
Apoptosis also mediates the involution of mammary glands. Apoptosis, does not 
play a significant role in clearing senescent cells (red blood cells, and intestinal 
enterocytes). Specific sets of caspases that function in cascades mediate apoptosis, 
at the end of which caspase 3 or 7 is responsible for killing the cells. In a mechanism 
called efferocytosis, apoptotic cells are engulfed by macrophages [16]. It is difficult 
to find free apoptotic cells in vivo, even in tissues where large numbers of cells 
undergo apoptosis, because efferocytosis is effective and rapid [17]. Apoptosis 
therefore requires pathways not just for destroying cells, but also for recruiting 
Macrophages (“find me”) [18, 19] and providing the macrophages with a signal 
(“eat me”) for cell engulfment [20, 21].
3. Recognition of dying cells
In early studies, cell shrinkage prior to cell death was associated with a process 
of non-inflammatory cell clearance, while inflammatory response is associated with 
cell swelling prior to death [12–14] (Figure 1). These morphologies were associated 
with apoptosis and necrosis processes. In recent decades, more molecularly diverse 
controlled cell death programs have been identified [2], with each type having a 
major impact on the biological consequences of cell death. Both apoptotic and non-
apoptotic dying cells demonstrate and release molecular signals in order to signal 
phagocytes and direct subsequent phagocytic and immune responses.
4. Efferocytosis
The term “efferocytosis” is derived from the Latin word “efferre” meaning “to 
take to the grave,” which describes the process of programmed cell removal (PrCR). 
In cell biology, efferocytosis is characterized as the swallowing and decomposition 
of apoptotic cells by phagocytes. The noteworthy point of efferocytosis is that this 
mechanism includes the production of anti-inflammatory cytokines and the inhibi-
tion of pro-inflammatory cytokines. This means that efferocytosis takes place in an 
immunologically silent state that mechanistically differs from the phagocytosis of 
pathogens and other opsonized particles [20] in which pro-inflammatory cytokines 
are produced. Recent evidence has shown that many types of cells have the ability to 
clear their neighboring dying cells, including both professional and non-professional 
phagocytes, although it has long been believed that apoptotic cells can only be 
cleared by efferocytosis by specialized cells. Professional phagocytes include macro-
phages and immature dendritic cells, while non-professional phagocytes are involved 
in epithelial cells, endothelial cells, and fibroblasts. The stages in which apoptotic 
particles are extracted by professional and non-professional phagocytes are the 
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same, although various kinetics have been recorded. In fact, the process of efferocy-
tosis is carried out at greater speed and capacity by trained phagocytes [22, 23].
4.1 Find-me signals
Signals produced by apoptotic cells usually involve two types: soluble molecules 
and complicated extracellular vesicles. Nucleotides such as adenosine triphosphate 
(ATP) and uridine triphosphate are among the most widely recognized find-me 
signals (UTP). In the environment, such nucleotides are released by apoptotic cells 
through the pannexin-1 channel. They bind purinoreceptor 2 (P2Y2) to the surface 
of the phagocytes, thus serving as short-range chemo attractants [22–27]. Recent 
studies have shown that certain mediators of oxidative stress can serve as find-me 
signals by activating monocyte recruitment towards suffering cells at risk of death. 
The release of oxidative stress mediators may be a physiological mechanism for the 
precautionary use of phagocytes before the onset of cell death, but it may also pro-
mote the pathogenesis of some conditions [1, 9, 28–31]. Lysophosphatidylcholine 
(LPC) is a lipid mediator formed and released from apoptotic cells by the calcium-
independent isoform of phospholipase A22 (iPLA2). LPC plays a part in the 
recruitment of macrophages by reacting with the G2 accumulation (G2A) receptor. 
G2A is a G-protein-coupled (GPCR) receptor that plays a role in the regulation 
of cell cycles, oncogenesis, immunity, and proliferation. G2A is found in macro-
phages, dendritic cells, neutrophils, mast cells, T lymphocytes, and B lymphocytes. 
Although awareness of this receptor has so far been restricted, its most important 
Figure 1. 
Recognition of apoptotic cells by phagocytes (The Engulfment Synapse). altered carbohydrate (aCHO), 
β2-glycoprotein I receptor (β2GPIR), brain-specific angiogenesis inhibitor (BAI-1), complement protein C1q 
(C1q), calreticulin (CRT), growth arrest-specific 6 (Gas6), intercellular adhesion molecule 3 (ICAM-3), Mer 
tyrosine kynase (MerTK), milk fat globule-EGF factor 8 protein (MFGE8), oxidized low-density lipoprotein 
(oxLDL), phosphatidyl serin (PtdSer), receptor for advanced glycation end products (RAGE), Src homology 
2 domain-bearing protein tyrosine phosphatase substrate-1 (SHPS-1), T-cell immunoglobulin mucin receptor 
(TIM), thrombospondin-1 (TSB-1).
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role as an LPC receptor is probably to enable the development of monocyte, neutro-
phil and lymphocyte recruitment chemo attractants.
Fractalkine (CX3CL1) is a find-me signal which is secreted from apoptotic human 
B cells in extracellular vesicles. Fractalkine acts as a chemokine which facilitates its 
recruitment into apoptotic cells by binding to its receptor (CX3CR1) on the surface 
of the phagocyte 13. Fractalkine also increases the expression of MFGE8, which plays 
a role as a bridging molecule, in phase 13 of efferocytosis. In addition, apoptotic cells 
can cause the release of a number of cytokines and chemokines, including MCP-1 
and IL-8, involved in the recruitment of monocytes and Tam-Horsfall protein 1 
(THP-1) neutrophils, by binding to Fas/CD95 [32].
4.2 Eat-me signals
By binding to their receptors on the surface of phagocytes, eat-me molecules 
produce intracellular signal cascades, rearranging the cytoskeleton and contribut-
ing to swelling. Eat-me signals are usually divided into two groups [33–35]. The first 
group consists of new emerging molecules, such as phosphatidylserine (PtdSer) or 
annexin I, on the surface of apoptotic cells. The second category consists of exist-
ing molecules changed on the surface of the apoptotic cells [e.g., conversion of the 
intercellular adhesion molecule (ICAM)-3 to CD31] or various modifications in 
the plasma membrane components (e.g., loss of plasma membrane asymmetry and 
increased external negative charges) (Figure 2). Among the new evolving mol-
ecules on the surface of apoptotic cells, PtdSer is the most popular and well-known 
eat-me signal. PtdSer is actually located naturally on the inner surface of the plasma 
Figure 2. 
Apoptotic cell clearance-a multi-stage process. ATP-binding cassette transporter (ABCA1), complement 
component 1q (C1q), chemokine C-C motif ligand 5 (CCL5), C-C chemokine receptor type 2 (CCR2), 
chemokine C-X-C motif ligand (CXCL), erythropoietin (EPO), epiregulin (EREG), growth arrest-specific 6 
(Gas6), heme oxygenase-1 (HO-1), interferon (IFN), interleukin (IL), Mer tyrosine kinase (MerTK), milk fat 
globule-EGF factor 8 protein (MFGE8), nitric oxide synthase 2 (NOS2), nuclear receptor subfamily 4 group 
A (Nr4a1), thrombospondin-1 (TSB-1), transforming growth factor β (TGF-β), tumor necrosis factor (TNF), 
vascular endothelial growth factor (VEGF).
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membrane, but is transmitted to apoptotic cells on the outer surface of the plasma 
membrane. Flippases are responsible for preserving an asymmetric distribution of 
phospholipids within the cell membrane in non-apoptotic cells. However, when the 
apoptosis message is given and caspases in apoptotic cells are activated, flippases 
become cleaved and inactive. Caspases also simultaneously activate scramblases in 
apoptotic cells and, as a result, PtdSer rapidly migrates to the outer surface of the 
plasma membrane [36–40].
PtdSer can bind directly to various surface receptors of phagocytes, including 
T-cell immunoglobulin mucin (TIM)-1, TIM-4, BAI-1, stabilin-2, and advanced 
glycation end-product receptors (RAGE). Among them, by binding to PtdSer, 
TIM-4 is crucial in the tethering of apoptotic cells. Of note, among all phagocytes, 
some of these receptors do not have the Same distribution [41–46]. Therefore, in 
the clearance of specific apoptotic cells, each phagocyte with a particular set of 
these receptors plays a certain function [32, 37–40, 47].
4.3 Bridging molecules
Two domains of receptor-binding have bridging molecules. The prey-binding 
domain of phagocytosis (PPBD) can, on the one hand, be connected to the surface 
of apoptotic cells. On the other side, the receptor-binding domain binds to phago-
cytes. [43, 48–53] A bridge between apoptotic cells and phagocytic cells is thus 
formed. PtdSer can be indirectly connected to phagocyte receptors by bridging 
molecules, in addition to its ability to bind directly to receptors on the phagocyte 
surface. MFGE8 is a bridging molecule which, on the one hand, binds to PtdSer 
on the surface of apoptotic cells and, on the other, binds to alpha-3/alpha-5 integ-
rins, thus acting as a bridge between apoptotic cells and macrophages in order to 
facilitate the tethering phase [44, 54–56]. After binding to membrane integrins, it 
generates signals within macrophages, by recruiting the CRKII-DOCK180-ELMO 
(Figure 3) complex and activating Rac1. These signaling pathways eventually 
result in a rearrangement of the cytoskeleton and thus, enabling macrophages 
in the removal of apoptotic cells***. In addition, MFGE8 induces the release of 
anti-inflammatory cytokines. The anti-inflammatory action of MFGE8 could take 
place in two ways: directly, through phagocytic capacity development, and indi-
rectly, through the modulation of lipopolysaccharide-activated intracellular signals 
(LPS) [57–61]. This subset of macrophages promotes tissue repair and angiogenesis 
through the production of vascular endothelial growth factor (VEGF) or epidermal 
growth factor (EGF), which is usually found at the stage of tumor promotion. 
Annexin I (AnxI) is a bridging molecule that is a normal intracellular protein but 
is transferred to the outer surface of the PtdSer [62] plaque-containing cell mem-
brane during apoptosis.
4.4 Other eat-me signals
While phosphatidylserine is a powerful and well-characterized eat-me signal, 
other signals may play a role in the identification and swallowing of dying cells 
[63]. Exposed LPC can bind to IgM on the plasma membrane of dying cells, which 
in turn binds to phagocyte Fc receptors, such as macrophages [15]. Therefore, LPC 
continues to serve as a find-me signal as well as an eat-me signal. Proteins present 
in the endoplasmic reticulum lumen, such as calreticulin, may be exposed to the 
plasma membrane of dying cells and, in the absence of no-eat-me signals, may 
serve as an intake-me signal (Figure 2). In coordination with complement C1q and 
mannose-binding lectin (MBL) [16, 17] phagocyte calreticulin is recognized by LDL 
receptor-related protein 1 (LRP1), also referred to as CD49 [64].
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4.5 Don’t-eat-me signals
Macrophages and other phagocytes are also able to detect live and viable cells 
through don’t-eat-me signals, in addition to their ability to distinguish apoptotic 
cells from pathogens through eat-me signals. The most important ligand that plays 
this role is CD47 [65–68]. The signal regulatory protein alpha (SIRP alpha) is the 
receptor on the surface of macrophages for this protein, the activation of which 
prevents swallowing even when there is PtdSer [69, 70]. Instead, on the surface of 
apoptotic cells, CD47 expression is suppressed so that their clearance can be cor-
rectly achieved. In transducing don’t-eat-me signals, CD31 is another important 
ligand. Although this protein is not as well-known as CD47, its inhibitory effect on 
phagocytes [69, 71–73] has been demonstrated by several studies. Another protein 
that has a critical role in the transduction of a don’t-eat-me signal is CD300a. The 
CD300a-mediated recognition of PtdSer and phosphatidylethanolamine inhibits 
efferocytosis, preventing swallowing at stage 22.
5. Mechanisms of engulfment
Efferocytosis is a closely regulated process that involves the synchronized 
swallowing of dead and dying cells, maturation of the phagosome, and then the 
Figure 3. 
Activation of the CRKII-DOCK180-ELMO complex within phagocytes. MFGE8-opsonised apoptotic cells 
are captured by avβ integrins in macrophages; then, the recruitment of the ELMO– DOCK180 complex is 
induced and finally, by activation of Rac1, cytoskeletal rearrangement occurs for phagocytosis. Brain-specific 
angiogenesis inhibitor (BAI-1), cellular apoptosis susceptibility protein (Cas), guanosine diphosphate (GDP), 
guanosine triphosphate (GTP).
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breakdown of phagolysosomal material. Each stage is regulated by molecular 
mechanisms that allow the engulfed cell to quickly break down and recover the 
engulfing phagocyte.
5.1 Uptake of dying cells
If a dying cell is recognized by the phagocyte, swallowing of the cell corpse 
requires rapid re-organization and synthesis of the plasma membrane to enable 
the dead cell to be effectively phagocytic internalized. Phagocyte motility and 
environmental sampling are allowed by a complex mesh of cortical actin fibres 
lying under the plasma membrane. The phagocyte initiates actin remodeling upon 
identification of a dying cell, which enables invagination and localised extravaga-
tion of the plasma membrane and, eventually, phagosome creation. Depending on 
the receptor involved, the signaling mechanisms that bridge receptor ligation to 
activation of actin remodeling and related pathways vary, but usually include coor-
dinated kinase activation (such as those from the SRK, SYK, and protein kinase C 
families) and phosphatase inactivation, like SHP1, processes that have been well 
reviewed [20]. Two primary pathways leading to the reorganization of actin occur 
during efferocytosis and both converge on a central regulator, the small GTPase 
RAC1 family of RHO. The activation of RAC1 is mediated by LRP1 and the adapter 
protein GULP96 in the first method, but the exact mechanism of how LRP1 and 
GULP activate RAC1 is not understood. The second RAC1 activation mechanism is 
based on the DOCK180 guanine nucleotide exchange factor (GEF) and the phago-
cytic regulatory protein engulfment and protein motility of cells (ELMO). Another 
GEF, called ‘TRIO’, loads GTP onto the small GTPase RHOG following receptor 
ligation by the dying cell, leading to ELMO [20, 74–76] recruitment. ELMO is then 
able to interact with DOCK180’s SH3 domain [77]. The DOCK180-ELMO complex, 
together, serves as a GEF for RAC1, leading to activation of RAC1. By activating 
nucleation-promoting factors of the WASP family, SCAR and WAVE, which recruit 
the ARP2/3 complex and work together to build an actin nucleation centre, RAC1 
is subsequently able to guide localized actin polymerization required to coat or 
grasp the cargo once triggered through either system [70, 78–80]. The ARP2/3 
complex binds existing actin filaments in addition to forming a nucleation center 
for de novo actin polymerization, enabling new actin synthesis while retaining 
actin networking and branching, processes that are crucial for the formation 
of phagosomes [81–86]. Although actin polymerization is a critical component 
of the creation of phagosomes and the successful capture of the dead cell, actin 
depolymerization is of equal importance for the plasma membrane splitting of the 
phagosome. Phagosome sealing processes are highly dependent on different phos-
phoinositides, including phosphatidylinositol 3,4,5-trisphosphate, which activates 
GTPase-activating proteins of the RHO family, resulting in the deactivation of 
GTPases, including RAC1, resulting in depolymerization [87–89]. To facilitate the 
phagosome separation, a concerted effort exists between actin depolymerization 
and dynamin. Dynamin 2 also directs the trafficking of the full early phagosome  
[23, 26] downstream.
5.2 Lysosomal degradation
The phagosome and cell corpse are on their way to a well-planned destructive 
end after being detected and captured by the dying cell [90]. The phagosome is 
linked to lysosomes, which include proteases, nucleases, and lipases that degrade 
the phagosome’s cargo. Changes to the phagosome, as discussed below, either trig-
ger or inhibit this fusion. In a multi-stage maturation process, the serine/threonine 
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kinase VPS15 increases the catalytic activity of the early phagosome membrane 
and the targeting of VPS34 [27, 91]. VPS15 binds to the active RAB5 directly and 
forms a complex with VPS34 [92]. The role of VPS34 in phagocytosis associ-
ated with microtubule-associated protein 1A/1B light chain 3 (LC3) is discussed 
further (LAP). The transition from early to late phagosomes is characterized by 
the acquisition of distinct biochemical markers, including small RAB7 GTPase 
markers, as well as the loss of early RAB5 markers. Late phagosomes are more 
acidic than early phagosomes due to increased proton pumping into the phago-
some lumen mediated by the multimeric protein complex vacuolar ATPase, which 
translocates H+ across endosomal and phagosomal membranes [36, 47]. RAB7 
and its effectors are needed for phagosome maturation, as RAB7 inhibition pre-
vents phagosome-lysosome fusion and results in phagosome acidification failure 
[32, 91]. RAB7-interacting lysosomal protein (RILP) and oxysterol-binding pro-
tein-related protein 1 (ORP1; also known as ORPL1) are found in late endosomes, 
phagosomes, and lysosomes [32]. By communicating directly with the molecular 
motor dynein-dynactin, these proteins organize microtubule-dependent vesicular 
trafficking of RAB7-positive compartments. RILP, dynein, intact microtubules, 
lysosome-associated membrane protein 1 (LAMP1), and LAMP 2 are involved 
in the fusion of late phagosomes with the lysosomal compartment [37]. LAMP1 
and LAMP2 are highly glycosylated membrane proteins that keep the lysosomal 
membrane intact and are needed for phagosome-lysosome fusion through inter-
action with RAB77 [37].
The formation of a Ca2+−dependent SNARE complex, composed of VAMP7 and 
syntax 7, aids the direct fusion of the mature phagosome with the lysosome [38, 39]. 
Syntaxine 7 and VAMP7 are both recruited to phagosomes, and phagosome–lyso-
some fusion is prevented when syntaxine 7 is knocked out [74, 76, 93–98]. The 
newly developed phagolysosome is distinguished by its high acidity (pH 4.5–5.0) 
and the presence of active cathepsins after fusion. Acidification is needed for the 
activation of lysosomal acid hydrolases, which promotes the degradation of the 
internalized cell body. In conjunction with other effectors such as oxidants, cationic 
peptides, and lipase, these hydrolytic enzymes mediate the lysosome’s potent 
destructive potential [40, 33].
5.3 Phagosome maturation related modifications
5.3.1 LC3 assisted phagocytosis
The phagosome may be changed to either promote or hinder maturation, 
affecting the degradation of phagosome material after fusion with lysosomes. 
During the LAP, one such shift occurs. A subset of proteins necessary for canoni-
cal autophagy in LAP, in combination with LAP-specific regulators, allows the 
LC3 family to be combined with the LAP family. LC3 family proteins facilitate 
autophagosomes in autophagy, as LC33 depletion also inhibits lysosome fusion 
[34]. FYCO1, a RAB7 effector protein, interacts with LC3 and PI3P to promote 
autophagosome-lysosome fusion [35]. Similarly, phagosome LC3 promotes 
phagosome-lysosome fusion to form a phagolysosome. The rubicon homologue 
PLEKHM1 interacts with both RAB7 and LC3 and can promote phagosome and 
endosome trafficking [48, 99]. These processes are most likely shared by auto-
phagia and phagocytosis, both of which are involved in lysosomal targeting and 
fusion. To date, it has not been thought that the ability to conjugate LC3 with the 
phagosome directly affects the lysosome’s functional potential: impaired matura-
tion and degradation seen in LAP-deficient cells and animals has not been linked 
to direct lysosomal defects [49, 50].
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5.4 Liver X receptors
Other pathways with roles in efferocytosis include the liver X receptors 
(LXRs) and the PPARs, nuclear receptor families that control genes involved in 
lipid metabolism and transport [100–103]. By engulfing a dying cell, a phagocyte 
can effectively double its lipid content, requiring an appropriate transcriptional 
response which is mediated by these nuclear receptors. LXR deficiency results in 
their inability to clear the apoptotic thymocytes in macrophages, but does not alter 
the swallowing of inert beads or other substrates [104]. Similarly, mice that are defi-
cient in LXRs in many tissues accumulate dead cells due to failure of in vivo effe-
rocytosis [104]. Pharmacologic LXR agonists increase efferocytosis and clearance 
by increasing the expression of receptors, including MERTK, both in cell culture 
and in vivo136. In addition, during efferocytosis, the existence of LXRs induces 
the expression of ABCA1 cholesterol transporters, which emit excess cholesterol 
[105], and genes involved in mitochondrial lipid oxidation, enabling excess lipids 
to catabolize effectively [105, 106]. Efferocytosis is caused similarly to LXRs by the 
PPAR family. In response to apoptotic cell engulfment, PPARγ expression occurs 
and remains elevated until efferocytosis [107] has been resolved. In combination 
with activation of LXRs, PPARγ activation has been demonstrated to enhance 
efferocytosis by macrophages [104]. In fact, inhibition of PPARγ by a pharmaceuti-
cal antagonist resulted in impaired efferocytosis [107].
5.5 Resolution of phagocytosis
After the phagosome has fused with lysosomes and its cargo has been degraded, 
a resolution mechanism restores homeostasis within the phagocyte, allowing for 
further phagocytosis. Since dying cells are not the only phagocytic cargo, the effect 
of phagocytosis can differ depending on what cargo is internalised. After lysosomal 
degradation in the form of efferocytosis, some of the components of the cell corpse 
can be recaptured and recycled for use by the phagocytic cell. Carbohydrates, 
amino acids, lipids and nucleotides are recycled to replenish cellular stores and can 
potentially be used as building blocks and sources of energy by the phagocytic cell 
[108]. The internalisation and degradation of cargo can also influence the activation 
of signalling pathways; for example, DNA that escapes degradation can activate 
the DNA sensing cGAS-STING pathway and contribute to the production of type 
I interferons, as discussed earlier. These events may lead to the loss of the immune 
tolerance of the apoptotic corpse and can potentially result in autoimmunity [109]. 
As described earlier, LAP facilitates rapid maturation and generation of phagoly-
sosomes and efficient degradation of cells and promotes the production of anti-
inflammatory cytokines, including IL-10, a method that promotes immune silence. 
On the other hand, LAP disruption decreases phagosome maturation, contributing 
to the activation of inflammatory signalling pathways and to the production of 
proinflammatory mediators for IL-1β and [110–113]. The exact mechanism that 
leads to this switch in cytokine production has not been well known in the absence 
of LAP. Furthermore, failure in LAP-deficient phagocytes to effectively degrade 
the cell corpse can result in the leakage of phagosome contents, such as DNA, into 
the cytosol, which in turn induces the production of type I interferon via STING 
[114] sensing. STING-dependent interferon expression by tumour-related macro-
phages in LAP-deficient mice in several cancer models promoted T-cell-mediated 
anticancer immunity [114]. Following efferocytosis, the phagocyte must restore 
the functions of cytoskeletal components such as actin and microtubules to ensure 
that its phagocytic capacity is maximised for additional [115–118]. This restoration 
of function has not been well studied in contrast with the upstream processes of 
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phagocytosis. However, such details can be inferred from studies investigating the 
effectors such as RAB27A in the events leading to phagocytosis. RAB27A negatively 
affects phagocytosis by prolonging the actin coating of nascent phagosomes, 
resulting in impaired transition to the stage of phagosome sealing [119]. Therefore, 
RAB27A and related effectors may be essential for the restoration of actin and other 
cytoskeletal networks following the completion of phagocytosis. It is evident, how-
ever, that cytoskeleton restoration after phagocytosis is an ATP-dependent process 
and may involve multiple components [120]. An additional function of recovery is 
the recycling or continued expression of membrane receptors to accept subsequent 
cargo. Impaired recycling results in reduced membrane expression of receptors such 
as TREM2 and TLR4, which recognize a variety of amyloids and pathogen products 
[121, 122] respectively, and can also reduce the membrane expression of dying cell 
recognizing receptors. This decrease in the available surface receptors can impair 
the endocytic and phagocytic capacity of the phagocyte cell, which means that 
these restorative events are necessary to ensure that the phagocyte will continue to 
recognize and clear phagocyte cargo.
6. Disease and efferocytosis
The fact that efferocytosis has so much redundancy in the detection of dying 
cells emphasizes its significance in pathophysiology. In reality, many autoimmune 
and inflammatory disorders are associated with defects in this stage, with inflam-
mation, aggravated tissue damage, and organ dysfunction resulting in uncleared or 
improperly cleared cell bodies. Defects in other aspects of the efferocytotic machin-
ery, on the other hand, could result in enhanced protection against certain diseases.
6.1 Systemic disease
The most common autoimmune disorder associated with compromised effe-
rocytosis is systemic lupus erythematosus (SLE), a chronic systemic autoimmune 
disease that affects multiple organ systems such as the lungs, kidneys, skin and 
central nervous system (CNS). Although uncleared dead cells are rarely detected 
when healthy tissue is examined under the microscope, dead cells can often be 
observed in the blood, skin, and lymph nodes of SLE patients, and the seriousness 
of the disease is closely correlated with defective in vitro efferocytosis and dead 
cell accumulation in vivo [123, 124]. Patients with SLE also exhibit high levels of 
circulating autoantigens, such as extracellular DNA, that bind autoantibodies to 
form immune complexes that accumulate or are deposited in the glomerular and 
vessel walls of the kidneys [125, 126]. Defects at almost every level of the efferocy-
tosis pathway are involved in the pathogenesis of SLE. Mice with genetic deletion 
that abrogates find-me signalling pathway components (e.g., development of S1P), 
eat-me signalling pathway components (e.g. TIM4, MFGE8, S protein, MERTK and 
C1q) and dead cell treatment components (LXRs, PPARs, ABCA1 and rubicon) all 
display progressive SLE-like disease.
6.2 Neurodegenerative diseases
Phagocytic cells called ‘microglia’ are present in the CNS. The phenotypically 
close to these resident phagocytes are the macrophages and clear dead cells and cel-
lular debris in the CNS [127]. However, other CNS cells, such as oligodendrocytes, 
astrocytes, and neuronal progenitors, can also act as mediators of efferocytosis. 
Like all organ systems, the CNS needs effective efferocytosis for homeostasis, but 
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efferocytosis is also essential for the reorganization of the neuronal circuits and 
for the initiation of regenerative response after injury [128]. Consequently, there 
are numerous neurodegenerative diseases associated with efferocytosis abnormali-
ties, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease [129, 130]. Multiple sclerosis may result from defects that are 
involved in cell corpse processing at multiple stages of efferocytosis, including pan-
nexin 1find-me signalling defects, MERTK eat-me signalling, and LXR alpha and 
LXRβ signalling. Decreased expression of the bridging molecule MFGE8 was also 
observed in a mouse model of Alzheimer’s disease and expression of the dominant 
negative MFGE8 mutant in microglia cells decreased swallowing of apoptotic 
neurons [131, 132].
6.3 Lung inflammation
In inflammatory diseases, the production of reactive oxygen species (ROS) by 
neutrophils is increased. ROS can induce RhoA signalling in phagocytes, thereby 
reducing the clearance of apoptotic cells through inhibition of efferocytosis. A 
number of lung inflammatory disorders, including chronic obstructive pulmonary 
disease (COPD), asthma, pulmonary fibrosis, and cystic fibrosis, may lead to 
impairments or inefficiencies during inflammation in the effective clearance of 
dying neutrophils [133].
On the other hand, antioxidants such as N-acetylcysteine (NAC) can increase 
the clearance of apoptotic cells by inhibiting ROS growth, thereby suppressing 
RhoA activity and increasing the output of TGF-β [134]. The swallowing and clear-
ance of apoptotic leukocytes can also be enhanced by Macrophages [77, 135–139] 
by anti-inflammatory drugs such as corticosteroids. In particular, protein S binding 
to apoptotic cells and MerTK (from the TAM family) upregulation on the surface 
of macrophages can mediate increased clearance of apoptotic debris induced by 
corticosteroids.
6.4 Atherosclerosis
Lipid oxidation and retention can cause local inflammation in the arterial wall 
and encourage atherosclerosis progression. Circulating monocytes can aggregate 
and differentiate into macrophages in atherosclerotic lesions, which can in turn 
swallow large amounts of lipids and transform into foam cells filled with fat 
droplets. Macrophage clearance of apoptotic cells occurs primarily in the intima 
in the early phases of atherosclerosis, and apoptotic cells are cleared quickly and 
effectively. The condition is different in the case of advanced atherosclerotic lesions 
(called plaques), where a large number of monocytes/macrophages are recruited 
into clear foam cell bodies and additional debris. In foam cell bodies, a large number 
of oxidised lipids are identified which can inhibit the process of efferocytosis by 
binding to CD14 and can increase the activity of Rho kinase in atherosclerotic [140, 
141]. As a result, macrophages do not effectively complete the process of efferocyto-
sis; they thus transform themselves into foam cells and then promote inflammatory 
responses by secreting pro-inflammatory cytokines, [109, 121, 142–144] and ROS. 
The clearance of apoptotic cells also decreases and progression towards secondary 
necrosis increases, thereby sustaining an unfavorable cycle that leads to atheroscle-
rosis progression and associated complications [145–147].
Therefore, macrophages and the efferocytosis system play a very important 
role in the development of atherosclerosis [135–139]. The accumulation within the 
plaques of apoptotic cells and the acceleration of atherosclerotic disease are the 
result of a defect in the separate mediators of efferocytosis [148]. A study showed, 
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for example, that Gas deficiency contributed to the development of atherosclerosis 
by reducing the recruitment of lesion phagocytes, while the Mer function defect 
prevented the clearance of apoptotic cells, which promoted the progression of 
atherosclerosis. Therefore, a detailed knowledge of the efferocytosis pathways 
regulated by this cell will open up promising windows for the treatment of ath-
erosclerotic disease because of the critical role of macrophages in atherosclerosis 
pathogenesis [149].
6.5 Cancer
Although efferocytosis plays a vital role in tissue homeostasis, since clearance 
of apoptotic cells is followed by immunosuppressive responses, its role in cancer 
can be detrimental to the host. Indeed, tumour tissue is subject to high-speed cell 
proliferation and apoptosis, and the process of apoptotic cell clearance, which is 
associated with anti-inflammatory responses, can encourage tumour escape from 
immune surveillance and encourage tumour progression. Therefore, some studies 
have shown that different ligands and receptors involved in efferocytosis may be 
over-expressed in certain tumour cells and may cause tumorigenesis [40]. Soki 
et al. have shown that prostate cancer patients’ tissue and serum exosomes have a 
higher degree of MFGE8 expression than controls and that efferocytosis caused by 
MFGE8 leads to macrophage polarisation towards an M2 phenotype that promotes 
tumour [33]. Furthermore, in human oral squamous cell carcinoma (SCC) surgical 
specimens, the immunohistochemical expression of MFGE8 has been associated 
with some clinical tumour characteristics, including size, stage and invasion 
patterns [34]. Intensified Mer TK signalling in tumour tissues has been associated 
with cancer development, metastasis, and resistance to care [35]. Some studies have 
also been carried out showing that inhibiting the activation of efferocytosis against 
cancer progression can be successful.
In the co-cultivation of prostatic cancer cells and macrophages, the use of anti-
bodies against MFGE8 substantially decreased the conversion of macrophages to 
the tumor-promoting M2 phenotype [33]. Tumor production has been minimized 
in mice by monoclonal antibodies to MFGE8. Consequently, inhibiting efferocytosis 
and preventing the expression of anti-inflammatory interleukins will improve the 
immune system’s efficacy and anti-tumor effects [99]. However, literature data on 
the impact of efferocytosis on cancer is troublesome, as there is also evidence that 
cancer progression may be promoted by a defective efferocytosis. For instance, 
cancer cells have been shown to express high levels of CD47 on their surface in 
order to escape from phagocytosis. Therefore, a new approach to cancer treatment, 
based on inhibiting the expression of CD47 by siRNA or monoclonal antibodies in 
tumour cells, has emerged to prevent the transduction of don’t-eat-me signals into 
macrophages and increase the phagocytosis of cancer cells [48, 49]. A significant 
point on this controversial topic is linked to anti-cancer medications. These drugs 
cause the death of cancer cells by [150–152]. Anti-cancer drug-induced cancer cell 
apoptosis, accompanied by increased expression of anti-inflammatory cytokines 
(TGFβ, PGE2, PAF and IL-10), is triggered by efferocytosis in the tumour setting. 
As a result, this process will lead to the silent anti-tumour response of the immune 
system [50]. In addition, it has been shown that anthracyclines (e.g., doxorubicin) 
promote the expression of eat-me signals on the surface of tumour cells, leading 
to immunogenic cell death [5]. Additionally, as described, during the apoptotic 
process, apoptotic cells begin to release ATP and UTP within 2 to 4 hours. These 
nucleoside triphosphates have been demonstrated to act as chemo attractants and 
to inhibit inflammatory responses in the recruitment of macrophages [11]. The 
use of chemotherapy drugs to induce apoptosis in tumour cells can increase the 
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release of nucleoside triphosphates up to 100 times higher, with a significant effect 
on inflammatory inhibition and suppression of the immune system, although the 
amounts of nucleotides released during apoptosis are low, so that their effects on 
immune response suppression are limited. Therefore, a serious reconsideration of 
anti-cancer drugs is anticipated in the coming years, by fully understanding the 
function of these agents in apoptotic tumour cell efferocytosis [51, 52] and the 
related therapeutic consequences.
7. Conclusion
From the point of view of molecular biology and its defects in the development 
of different diseases, this chapter explores the mechanism of efferocytosis. Just a 
few examples of the potential effect of disrupted efferocytosis on human diseases 
are cancer, autoimmune diseases, lung inflammation and atherosclerosis. However, 
impaired clearance of apoptotic cells, including neurodegeneration, skeletal altera-
tions, cardiac growth, electrical impulse propagation and post-injury recovery, 
angiogenesis and wound healing, is believed to be involved in many other diseases 
with unfavorable prognosis and processes. In general, in an inflammation-silenced 
environment, efferocytosis involves many cells and molecular steps leading to the 
removal of apoptotic cells. Find-me and eat-me signals are secreted by apoptotic 
cells for this function, while phagocytic cells often work to clear apoptotic debris 
with the aid of bridging molecules. Anti-inflammatory interleukins are secreted 
after the engulfment of apoptotic cells. In fact, cancer progression can be increased 
by both defective and enhanced efferocytosis. Overall, it is possible to inhibit or 
activate the receptors associated with this process with accurate knowledge of the 
molecular mechanisms involved in the efferocytosis process and to target strongly 
for a new window in the treatment of many human diseases.
8. Future perspectives
Efferocytosis is regulated by a number of factors, including complex membrane 
lipids and multiple effector proteins. These factors are responsible for functions 
including dead cell recognition, phagocytosis activation, and, finally, cell corpse 
degradation. The multi-step process from cell death to cell clearance, as previously 
mentioned, is delicate, demonstrating the importance of efferocytosis in develop-
ment, homeostasis, and pathophysiology. The ability of phagocytes to clear cellular 
debris is required for the homeostatic function of nearly every major physiological 
system. Efferocytosis dysfunction induces serious disease, while activation of 
efferocytosis encourages immune silence by processing anti-inflammatory signals, 
clearing apoptotic cells, and involving the LAP machinery. Since current research 
indicates that efferocytosis and LAP involvement are beneficial in many environ-
ments, inducing an inflammatory response in the treatment of various malignancies 
by inducing LAP and efferocytosis may be beneficial. The production of therapeu-
tics targeting components of these pathways can increase the efficacy of current 
cancer therapies such as checkpoint blockade by raising the immunogenicity of 
apoptotic tumor cells. Since efferocytosis and associated molecular mechanisms 
are still being studied, new insights into the activation and regulation of the dying 
cell response are likely to lead to the discovery of new cancer, autoimmunity, 
neurodegeneration, and beyond treatment paradigms. Efferocytosis is regulated 
by a number of factors that mediate functions such as dead cell identification and 
activation of the multi-step process from cell death to cell clearance, demonstrating 
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the importance of efferocytosis in growth, homeostasis, and pathophysiology. 
The ability of phagocytes to clear cellular debris is required, at least in part, for the 
homeostatic function of almost every major physiological system. Efferocytosis 
dysfunction causes severe disease, while activation of efferocytosis promotes 
immune silence through anti-inflammatory signal processing in the context of 
clearing apoptotic cells and the involvement of the LAP machinery. Since current 
research suggests that efferocytosis and LAP involvement are beneficial in a variety 
of settings, inducing an inflammatory response by inducing LAP and efferocytosis 
can be beneficial in the treatment of various cancers. Established cancer therapies, 
such as checkpoint blockade, may be improved by developing therapeutics that 
target components of these pathways, such as enhancing the immunogenicity of 
apoptotic tumor cells.
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